Introduction
Diabetes mellitus is one of the major causes of premature death and disability, mainly due to cardiovascular complications. With the depressing forecast of 366 million people suffering from diabetes by 2030, the epidemic represents a sword of Damocles for health care in most countries [ 1 ] . The increasing prevalence of obesity is considered a "fi restarter" for type 2 diabetes.
Heart failure is prominent among the complications of diabetes. Diabetic cardiomyopathy (DCM) was historically described as a disease process that affects the myocardium independently of macrovascular complications currently associated with common risk factors such as arterial hypertension and dyslipidemia [ 2 ] . Although many of the structural and functional abnormalities of the heart that characterize DCM have been described, the disease's origins are still unclear. The pathogenesis of DCM is an active fi eld of investigation, and we wish to refer the reader to other excellent reviews published recently on the matter [ 3 , 4•• , 5 ] . We report recent advances in research supporting the idea that DCM may originate from the heart's failure to adapt to chronic changes in cardiac metabolism.
Evidence for DCM in Humans

Structural and functional features of diabetic cardiomyopathy
In the 1970s, the Framingham Heart Study demonstrated an increased incidence of congestive heart failure in diabetic patients of both sexes that was independent of age, obesity, hypertension, coronary artery disease, and hypercholesterolemia [ 6 ] . Echocardiographic studies on independent populations and the more recent use of transmitral infl ow with tissue Doppler analysis have established the typical pattern of alterations characterizing DCM [ 7 ] . DCM is a combination of left ventricular (LV) structure abnormalities (concentric remodeling/hypertrophy) with diastolic dysfunction that may precede the development of systolic dysfunction and eventually progress to overt heart failure. Heart failure is defi ned as a clinical syndrome in which exercise intolerance is associated with LV dysfunction of the heart [ 8 ].
Systemic and myocardial metabolic shifts
When considering heart failure in patients with diabetes, one must fi rst consider the metabolic derangements of diabetes mellitus: hyperglycemia, insulin resistance (for type 2 diabetes), and dyslipidemia with increased levels of circulating nonesterifi ed fatty acids (NEFA). The resulting changes in nutrient supply and uptake at the cardiac myocyte's level dramatically affect the way the heart converts chemical energy to mechanical energy. Exact mechanisms still need to be worked out. According to studies performed in animal models, intramyocardial lipid accumulation is a main feature of DCM [ 3 , 4•• , 5 ] , and the concept of cardiac lipotoxicity is discussed further below. Although cardiac steatosis was already considered as a possible cause of sudden death during the 19th century [ 9 ] , its presence and its involvement in DCM development in humans have been ignored for a long time.
We have observed intramyocardial lipid accumulation in the failing heart of patients with diabetes that resem-bles the lipotoxic Zucker diabetic fatty (ZDF) rat heart [ 10 ]. More recent work by others has shown that cardiac steatosis is found in patients with impaired glucose tolerance and precedes the onset of type 2 diabetes mellitus and LV systolic dysfunction [ 11•• ] . Intramyocardial lipid accumulation in type 2 diabetic patients also directly correlates with impaired contractility and decreased capability of myocytes to adapt after infarction [ 12 ] . Increased plasma NEFA levels and myocardial triglyceride accumulation are correlated with impaired diastolic function in healthy young people [ 13 ] . Lastly, abnormal LV energy metabolism in obese insulin-resistant men precedes functional and structural remodeling of the heart [ 14 ]. Thus, a metabolic derangement of the heart characterized by an intramyocardial lipid accumulation is likely to contribute to DCM development in humans.
The Pathogenesis of DCM
Animal models of DCM
Most of the molecular mechanisms involved in DCM pathogenesis have been (and are) investigated with rodent animal models of type 1 or type 2 diabetes mellitus ( Table  1 ) . Because DCM is a complex, multifactorial disease, it is unlikely that there will ever be an animal model that presents all the aspects of the human syndrome. The disease's mechanisms are investigated separately in a wide spectrum of models [ 15 ] .
The models consist of animals with defective insulin actions or signaling, with an altered cardiac glucose and/or fatty acid use, with enhanced oxidative stress, or with enhanced cardiac fi brosis. The most popular animal models include the chemical ablation of the β cells of the pancreas (streptozotocin [STZ]-treated rodents), animals spontaneously defi cient in leptin signaling (ob/ob and db/ db mice, ZDF rats), and transgenic animals with a cardiac-specifi c lipotoxicity. These models are not without limitations. In contrast to humans with diabetes mellitus, rodents are resistant to developing atherosclerotic lesions and ischemia. At the same time, animals, unlike human patients, are often not treated for diabetes. Nonetheless, rodent models have served to identify several defects that are likely to be responsible for DCM development in humans. Recent studies using broad transcriptomic or proteomic approaches give a good overview of the profound modifi cations that affect the heart in diabetes mellitus [ 16 , 17 ] . Besides the dysregulation of circulating factors that contribute to heart fi brosis and hypertrophy, major intramyocellular changes focus on cardiac metabolism and a subsequent series of defects in mitochondrial function, in reactive oxygen species (ROS) generation or dissipation, and in calcium homeostasis.
Circulating factors, apoptosis, and cardiac fi brosis
Impaired contractile function seems to be partly caused by cell necrosis or apoptosis and myocardial fi brosis, 
